Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:
- Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00)
- Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal cancer (8:58)
- Approach to managing Stage III colon cancer with ctDNA-positive results after adjuvant treatment (13:35)